Compare
Viskase Holdings, Inc. vs Scilex Holding Co vs Monte Rosa Therapeutics, Inc. vs Vor Biopharma Inc.
| Latest fiscal year | Viskase Holdings, Inc. VISKRevenue covers only part of its income (partial revenue) | Scilex Holding Co SCLXRevenue covers only part of its income (partial revenue) | Monte Rosa Therapeutics, Inc. GLUE | Vor Biopharma Inc. VOR |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $30.25M | $123.67M | n/a |
| Revenue growth (YoY) | n/a | -46.5% | +63.5% | n/a |
| Gross margin | n/a | 65.0% (computed) | n/a | n/a |
| Operating margin | n/a | n/m | -43.8% | n/a |
| Net margin | n/a | n/m | -31.2% | n/a |
| Net income | -$3.41M | -$374.05M | -$38.63M | -$695.98M |
| EPS (Diluted) | -$0.07 | -$36.48 | n/a | -$70.50 |
| Operating cash flow | -$3.01M | $3.82M | -$22.80M | -$142.71M |
| Free cash flow | n/a | $3.68M | -$27.50M | -$143.65M |
| Cash & equivalents | $42.57M | $4.96M | $129.88M | $396.49M |
| Total assets | $42.81M | $364.98M | $448.66M | $464.13M |
| Total liabilities | n/a | $576.73M | $215.60M | $628.44M |
| Shareholders' equity | -$2.52M | -$207.78M | $233.06M | -$164.31M |
| Return on year-end equity | n/a | n/a | -16.6% | n/a |
| Shares outstanding | 74.21M | 7.03M | 65.54M | 38.72M |
Revenue, most recent five fiscal years
| Fiscal year | Viskase Holdings, Inc. | Scilex Holding Co | Monte Rosa Therapeutics, Inc. | Vor Biopharma Inc. |
|---|---|---|---|---|
| Latest | n/a | n/a | $123.67M Ended 2025-12-31 | n/a |
| 1 year earlier | n/a | n/a | $75.62M Ended 2024-12-31 | n/a |
| 2 years earlier | n/a | n/a | $0 Ended 2023-12-31 | n/a |
| 3 years earlier | n/a | n/a | n/a | n/a |
| 4 years earlier | n/a | n/a | n/a | n/a |